Sanofi
Nasdaq SNY · Paris, France
Works in Cardiovascular · Dermatology · ENT · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Ophthalmology · Psychiatry · Renal & urogenital · Respiratory · Women's health
Sanofi is a clinical trial sponsor based in Paris, France, listed as Nasdaq SNY. It has 152 active clinical trials with 448,310 planned participants, across 17 therapeutic areas. Since 2021 it has completed 277 trials and stopped 81 early.
Trial track record · since 2021
Financials · Nasdaq SNY
Fundraising
Pipeline · 152 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
1 approved drug application with a product on the market.
Questions about Sanofi
Sanofi is lead sponsor of 152 active clinical trials on ClinicalTrials.gov, with 448,310 planned participants, in Cardiovascular, Dermatology, ENT, Genetic & rare and other areas. Since 2021 it has completed 277 trials and stopped 81 early.
Sanofi is based in Paris, France and is listed as Nasdaq SNY. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Sanofi; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-16.
Approve Suite is not affiliated with Sanofi. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.